EP3914257

COMBINATION OF A BCL-2/BCL-XL INHIBITOR WITH OSIMERTINIB

  • Status:
    EP einkaleyfi: Þýðing ekki lögð inn
  • EP appl. date:
    1.4.2021
  • EP published:
    27.12.2023
  • EP application number:
    21754882.5
  • Max expiry date:
    31.3.2041
  • Title in English:
    COMBINATION OF A BCL-2/BCL-XL INHIBITOR WITH OSIMERTINIB
  • Language of the patent:
    English

Timeline

Today
1.4.2021EP application
27.12.2023EP Publication

Owner

  • Name:
    Ascentage Pharma (Suzhou) Co., Ltd.
  • Address:
    Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215000, CN
  • Name:
    Ascentage Pharma Group Corp Limited
  • Address:
    9/F., Wah Yuen Building 149 Queen's Road Central, Hong Kong 999077, CN

Inventor

  • Name:
    ZHAI, Yifan
  • Address:
    Jiangsu 215000, CN
  • Name:
    YANG, Dajun
  • Address:
    Jiangsu 215000, CN

Priority

  • Number:
    PCT/CN2020/084145
  • Date:
    10.4.2020
  • Country:
    WO
  • Number:
    202110344288
  • Date:
    31.3.2021
  • Country:
    CN

Classification

  • Categories:
    A61K 31/675, A61P 35/04, A61P 35/00, A61K 45/06, A61K 31/519, A61K 31/506, A61K 31/496, A61K 31/337, A61K 31/407

Upload documents